EGFR and non-small cell lung carcinoma: Base editing technology demonstrates unique advantages in this field, for example, the use of BE4max to accurately introduce the EGFR L858R mutation in non-small cell lung cancer (NSCLC), which successfully mimics the clinical (Harrison et al., 2020).